Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

INTRODUCTION: HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations ab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Int AIDS Soc
Autores principales: Gagliardini, Roberta, Rossetti, Barbara, Bianco, Claudia, Rusconi, Stefano, Colafigli, Manuela, Prinapori, Roberta, Francisci, Daniela, Fantauzzi, Alessandra, Orofino, Giancarlo, Vignale, Francesca, Di Giambenedetto, Simona, De Luca, Andrea
Formato: Artigo
Lenguaje:Inglês
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P286
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225435/
https://ncbi.nlm.nih.gov/pubmed/25397562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19818
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares